Full-Time
Manager – Production
API
Piramal Pharma
1,001-5,000 employees
CDMO for drug development and manufacturing
No salary listed
Nizamabad, Telangana, India
In Person
 Biology & Biotech (2) |
|---|
| , |
- BE/B.TECH ( CHEMICAL)
- To be responsible for the overall activities of plant.
- To be responsible for the production and manpower planning of plant.
- To ensure that products are produced and stored according to appropriate procedures & documentation in order to obtain/maintain the required quality.
- To review and ensure the batch production records (BMR & BPR etc.) are executed as per standards.
- To ensure that the qualification of Equipment’s and Instruments are done.
- To ensure that the appropriate validations are done for products.
- To check and ensure minimum stock of consumables, Log books and Status Labels.
- Ensuring preventive maintenance of all equipment’s and instrument calibrations as per schedule.
- Co-ordinate with service departments (QA, QC, IT, stores, E&M, EHS, projects, SCM & Finance) for various production related activities.
- To ensure and verify the SAP stocks for RM, intermediates and FG materials
- To attend GMP and safety trainings & implement the trainings outcome at workplace.
- To ensure that the required initial and continual training of department personnel are carried out and adapted according to the need
- To check and ensure production related inputs in SAP system and FG transfer.
- To be responsible for investigations for market complaints, deviations, quality incidents and take appropriate CAPA against the non-conformity / Root cause.
- Participation in management reviews on process performance, quality and advocating continual improvement.
- To be responsible for timely, effective communication and escalation process exists to raise quality issue to the appropriate levels of management.
- To be responsible for production activities are being followed as per the pre-defined procedure and cGMP.
- To be responsible for audit readiness and compliance within the stipulated timelines.
- To be responsible for compliance of legal and other requirements related to ISO and OHSAS standards
- To be responsible for identification of risk, hazards, environmental aspects and evaluation and review the same.
- To be responsible to develop the objective and targets under the ISO and OHSAS standards
- Identify the EHS training needs for awareness and competence of department personnel.
- To be responsible for the work of his senior in the absence of senior or authorization from senior.
- Responsible to handle all the QMS documentation works such as Change controls, Deviation investigations, Market complaint investigations, Corrective and Preventive actions, Preparation / review of protocols, Qualification & validation activities, SOP preparation or revision, Batch record preparation / review / approval.
- Complete the assigned training activities in LMS within timeline and should provide trainings to associates as per requirement in LMS
- Handling of Internal and External audits, Visits, Safety audits etc. and their compliance.
- To involve in the CSV (Computer System Validation) related activities.
- To perform review activities in ENSUR, Docusign & Trackwise system
- To perform approval of training contents / questionnaires in LMS
Piramal Pharma operates through three divisions: Piramal Pharma Solutions (PPS), a CDMO that provides development and manufacturing services across the drug lifecycle for clients worldwide; Piramal Critical Care (PCC), which produces complex hospital generics, including inhaled anesthetics; and the Consumer Products Division (CPD), selling consumer health brands in India such as Littles and Lacto Calamine. PPS supports drugs from development to production for customers; PCC makes hospital-grade generics; CPD distributes well-known Indian consumer health products. The company stands out with its global manufacturing scale, integrated network, and specialized strengths in complex hospital generics and inhaled anesthetics, alongside a strong portfolio of Indian consumer brands across more than 100 countries. Its goal is to grow its life-science ecosystem by expanding PPS and PCC capabilities and broadening CPD’s consumer brands across markets.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
India
Founded
2020
Simplify's Take
What believers are saying
- Kenalog acquisition from BMS adds $30-40M annual revenue via 6,000+ hospital network.
- ADCelerate program captures 80% biotech funding surge in H2 2024 for cancer therapies.
- Consumer Healthcare Power Brands grow 24% YoY with 48% e-commerce sales increase.
What critics are saying
- Lonza's US ADC expansions outpace Piramal's Riverview facility in 12-24 months.
- Chinese CDMOs like WuXi STA cut sterile injectables margins below 13% in 12-18 months.
- Inventory destocking contracts CDMO revenue 10% into FY27.
What makes Piramal Pharma unique
- Piramal Pharma Solutions delivers end-to-end CDMO services across drug lifecycle with 17 global facilities.
- Piramal Critical Care leads in inhaled anesthetics and complex hospital generics across 100+ countries.
- AbbVie JV dominates Indian ophthalmology market with glaucoma and dry eye treatments since 1996.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Piramal Pharma who can refer or advise you
Benefits
Stock Options
Company News
Cleanroom flooring overhaul completed at Piramal Healthcare. A major cleanroom flooring overhaul has been completed at Piramal Healthcare Limited's Northumberland facility, with Kemtile replacing 650m^2 of pharmaceutical cleanroom floor in a 28-day installation programme. Cleanroom flooring replacement at Morpeth site. Piramal's Morpeth site is a fully integrated production facility offering Active Pharmaceutical Ingredients (APIs), oral solid drug product development, clinical supply, commercial manufacturing and packaging services for both innovator and generic pharmaceutical companies. The £250,000 flooring project marks a significant upgrade to the previous surface, which had been in place for 56 years. Kemtile, a division of international flooring manufacturer Stonhard, installed the new Stonhard GS flooring system, designed to deliver durability, chemical resistance and seamless hygiene suitable for pharmaceutical cleanroom environments. To enhance performance, Kemtile applied two coats of Stonkote HT4 with a textured finish to maximise slip resistance, and installed Polysto hygienic coving throughout alongside a new channel drain. Project delivery and industry collaboration. Kemtile's Jay Livingstone said: "It's built to meet the rigorous standards that Piramal's operations require and will keep performing for decades to come." Martin Graham, Director of Engineering, Facilities and IT at Piramal Pharma Solutions, praised the team's efforts. "A huge thank you to Kemtile, especially Steve Lyon, Declan Strain and Jay Livingstone together with their install team for their perseverance and commitment throughout this intensive project," he said. Experts from Piramal Engineering and Pharma Site Services Limited were also acknowledged for their support in floor preparation and cleaning activities. Graham added: "Projects like this demonstrate the importance of experience, planning, and collaboration in achieving outstanding results." Kemtile's experience in pharmaceutical environments. Kemtile has more than 40 years' experience supplying hygienic, bespoke flooring systems to cleanroom and pharmaceutical facilities. The company regularly advises manufacturers on complete floor system requirements, offering site surveys, specification, design, groundworks, drainage, site supervision, health and safety compliance and installation.
Piramal Pharma reported early signs of CDMO business recovery with improved RFPs and order inflows during its Q3 2026 earnings call. The company maintained a strong regulatory track record, clearing 30 inspections including 2 US FDA inspections without OAIs. However, the company faced a 3-4% year-over-year revenue decline due to inventory destocking and slower early-stage order inflows. EBITDA margins remained at 11% for the quarter. The consumer healthcare business grew 20% in Q3 and 16% over nine months. Piramal acquired Kenalog from Bristol-Myers Squibb, expecting annualised revenues of $30-40 million. The product aligns with the company's hospital channel strengths and has limited competition due to complex manufacturing requirements. Management expects momentum from improved US biopharma funding to support healthy growth in FY27.
Piramal Pharma acquires Kenalog(R) branded injectable product. Piramal Pharma has acquired Kenalog(R), a branded commercial injectable product, from Bristol-Myers Squibb Company (BMS) for an upfront consideration of US$ 35 million. Contingent consideration up to US$ 65 million is payable on agreed operational and financial milestones. The acquisition is expected to leverage Piramal's distribution network and broaden its product portfolio, especially in the US, Europe & Asia Pacific regions. Kenalog(R) acquisition. Piramal Pharma Limited has entered into definitive agreements to acquire Kenalog(R) and its associated brands from Bristol-Myers Squibb Company (BMS). Deal terms. The acquisition includes an upfront consideration of US$ 35 million. Furthermore, contingent consideration up to US$ 65 million will be payable based on the achievement of certain operational and financial milestones. The transaction is subject to customary closing conditions. About Kenalog(R). Kenalog(R) is a branded commercial injectable product containing Triamcinolone Acetonide, a synthetic corticosteroid used as an adjunctive therapy in acute gouty arthritis, rheumatoid arthritis, and other conditions. It is currently marketed by BMS across 15 countries under trademarks such as Kenalog(R), Kenacort(R), Trigon(R), and Adcortyl(R). Strategic rationale. The acquisition of Kenalog(R) is expected to leverage Piramal's extensive distribution network, which spans over 6,000+ hospitals in more than 100 countries. This move is also anticipated to broaden Piramal's CHG product portfolio, creating new growth opportunities, especially in the US, Europe, and Asia Pacific markets.
Piramal Pharma secures $216 million financing with corporate guarantee.